文献速递支持与姑息治疗

微卫星稳定实体瘤中每兆碱基≥10个突变的抗PD-1免疫治疗反应率

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项单中心回顾性队列研究纳入1678例接受免疫检查点抑制剂治疗的16种癌症患者,评估通用高肿瘤突变负荷(TMB≥10个突变/兆碱基)对疗效的预测价值。结果显示高TMB肿瘤的反应率在部分癌种中更高,但通用阈值预测价值有限,癌种特异性阈值可能更优。

要点

  • 通用TMB≥10突变/兆碱基仅能在16种癌症中的11种观察到更高反应率。
  • TMB阈值提高至>18突变/兆碱基时,整体反应率可达56%。
  • 癌种特异性TMB阈值在14/16种癌症中数值上提高反应率区分度。

核心结论

  • 通用TMB≥10突变/兆碱基的预测价值有限,因癌种间差异大且与生存关联不明确。
  • 癌种特异性TMB阈值可能比通用阈值更能预测免疫检查点抑制剂反应。

研究设计与样本

  • 患者涵盖16种癌症类型,肿瘤接受下一代测序,暴露定义为至少1剂免疫检查点抑制剂。

主要发现

  • 1678例中男性924例(55%),中位年龄64岁(四分位距55-71岁)。
  • 按通用阈值10突变/兆碱基,416例肿瘤(25%)归类为高TMB,比例从肾癌0%至黑色素瘤53%(113/214)。
  • 高TMB肿瘤仅在16种癌症中的11种相比低TMB肿瘤有更高反应率。
  • 全队列中,TMB>10突变/兆碱基反应率为41%(169/416),TMB>18突变/兆碱基(最高TMB十分位数)反应率为56%(90/161)。
  • 按癌种特异性阈值,457例肿瘤(27%)归类为高TMB,癌种内反应率从胰腺癌4%(1/26)至黑色素瘤70%(46/66)。

关键数值与推荐

  • 美国FDA于2020年6月批准帕博利珠单抗用于TMB≥10突变/兆碱基的任何组织学类型恶性实体瘤。
  • 癌种特异性阈值下,高TMB相比低TMB肿瘤在14/16种癌症中数值上反应率更高。

临床怎么用

  • 临床决策中应认识到通用TMB≥10突变/兆碱基阈值的预测价值因癌种而异。
  • 考虑癌种特异性TMB阈值以更精准筛选免疫检查点抑制剂获益人群。

局限性

  • 单中心回顾性设计可能限制结果的普适性。
  • 研究假设在数据收集后、分析前才形成。
  • TMB高与生存结局的关联不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In June 2020, the US Food and Drug Administration approved the anti-programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of any histologic type with high tumor mutational burden (TMB; ≥10 mutations per megabase). The predictive value of this universal cutoff for high TMB is not well understood. OBJECTIVE: To examine the performance of a universal definition of high TMB in an independent cohort of patients with solid tumors treated with immune checkpoint inhibitors. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 1678 patients at a single cancer referral center treated with immune checkpoint inhibitors from January 1, 2015, to December 31, 2018. Patients had 16 different cancer types and were treated with anti-programmed cell death 1 or programmed cell death ligand-1 immunotherapy. Tumors underwent next-generation sequencing. EXPOSURES: At least 1 dose of immune checkpoint inhibitors. MAIN OUTCOMES AND MEASURES: Best overall response to immune checkpoint inhibitor therapy. The hypothesis tested was formulated after data collection and prior to analysis. RESULTS: Of 1678 patients, 924 (55%) were male, and the median age was 64 years (interquartile range, 55-71 years). Using the universal cutoff of 10 mutations per megabase, 416 tumors (25%) were categorized as having high TMB. Across cancer types, the proportion of TMB-high tumors ranged from 0% of kidney cancers to 53% of melanomas (113 of 214). Tumors categorized as TMB-high had higher response rates compared with TMB-low tumors in only 11 of 16 cancer types. In the entire cohort, response rates increased with higher cutoffs for TMB-high categorization, reaching 41% (169 of 416) for TMB more than 10 and 56% (90 of 161) for TMB more than 18, the highest TMB decile. Response rates also increased with TMB percentile within cancer type. Using cancer-specific cutoffs, 457 tumors (27%) were categorized as TMB-high. Response rates within cancer type ranged from 4% for pancreatic cancer (1 of 26) to 70% for melanoma (46 of 66). Cancer-specific cutoffs were associated with numerically higher response rates for TMB-high compared with TMB-low tumors in 14 of 16 cancer types. CONCLUSIONS AND RELEVANCE: The data from this cohort study validate the finding of generally higher response rates following immune checkpoint inhibitor therapy for tumors with TMB of 10 or more mutations per megabase, across multiple cancer types. However, the predictive value of a universal numerical threshold for TMB-high was limited, owing to variability across cancer types and unclear associations with survival outcomes. Further investigation will help define cancer type-specific TMB cutoffs to guide decision-making.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Valero C, Lee M, Hoen D, et al. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol. 2021. PMID: 33599686. doi:10.1001/jamaoncol.2020.7684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。